2 May 2016 - The TGA registered two new chemical entities (medicines) and two new blood products in April 2016.

The new medicines are:

• Cobimetinib hemifumarate (Cotellic) - use in combination with vemurafenib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600 mutation
• Avanafil (Spedra) - treatment of erectile dysfunction in adult males

The new blood products are:

• Octocog alfa (Kovalty) - treatment and prophylaxis of bleeding in patients of all ages with haemophilia A (congenital factor VIII deficiency)
• Susoctocog alfa (Obizur) - treatment of bleeding episodes in adults with acquired haemophilia A

For more details, go to: http://www.tga.gov.au/prescription-medicines-registration-new-chemical-entities-australia